Opioid-positive urine drug screen during treatment with oral naltrexone and the clinical implications

• Päätekijät: Elena R. Beauregard, PharmD, BCPS (Tekijä), Elizabeth G. Maguire, PMHNP-BC (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: American Association of Psychiatric Pharmacists, 2024-04-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Introduction Naltrexone is an opioid antagonist that is FDA approved to treat alcohol dependence and opioid dependence. It is available as an oral tablet and an extended-release injectable suspension. Naltrexone is metabolized to the primary metabolite, 6-β-naltrexol, and to 2 minor metabolites, 2-h...